Introduction
============

In the largest genome-wide association study meta-analysis of lipids published to date, only ten loci were associated with both LDL cholesterol (LDLC) and triglycerides (TG) levels significantly ([@ddw151-B1]). Of these, a locus on Chr19p13.11 has also been associated with incidence of coronary artery disease (CAD), as shown in both case--control and prospective cohort studies of Caucasians and Asians ([@ddw151-B1]). The haplotype in this locus tagged by the C minor allele of rs10401969 has been associated with reduced plasma LDLC and/or TG in African American, Hispanic and Native American populations ([@ddw151-B3]), as well as in several populations of European ancestry ([@ddw151-B1],[@ddw151-B4],[@ddw151-B11]). This locus has also been associated with Type 2 diabetes ([@ddw151-B11],[@ddw151-B15],[@ddw151-B16]), hepatic steatosis, non-alcoholic fatty liver disease ([@ddw151-B17]) and body mass index ([@ddw151-B21]), suggesting that genetic variation within this region has a broad impact on human metabolism.

Recently, three studies have implicated *TM6SF2* as the causative gene within the Chr19p13.11 locus. Exome sequencing studies identified an association between rs58542926, a non-synonymous (Glu167Lys) variant in *TM6SF2*, and risk of myocardial infarction and non-alcoholic fatty liver disease ([@ddw151-B22],[@ddw151-B23]). Expression of the recombinant *TM6SF2* variant encoding p.Glu167Lys in HepG2 cells resulted in 50% less protein compared to wildtype. *Tm6sf2* knockdown in an AAV murine model ([@ddw151-B23]) increased hepatic TG and decreased very low-density lipoprotein (VLDL) secretion, consistent with the effects reported *in vitro* ([@ddw151-B24]).

Notably, rs58542926 is in very strong linkage disequilibrium (LD) with rs10401969 in Europeans (*r*^2^= 0.95 and D′ = 1 in 503 EUR, 1000 Genomes Project, Phase 3). In fact, in individuals of European descent, rs10401969 (EUR MAF = 7.1%) resides in a large LD block that extends ∼360 kb across at least 14 genes and contains 32 other genetic variants that are all in strong LD (*r*^2^\> 0.8) with rs10410969. Although it may be simplest to attribute all of the phenotypic associations with the 19p13.11 haplotype described above to one causal gene, such as *TM6SF2*, the complex genetic architecture of this region suggests other possibilities. For instance, any number of the 33 variants in strong LD (and perhaps rarer SNPs, via synthetic association) ([@ddw151-B25]) could have functional effects that contribute to the associated phenotypes, perhaps by acting on different genes. In addition, even a single variant could impact multiple genes that contribute to the same phenotype, especially because functionally related genes are often clustered in the genome. Consistent with these possibilities, Blattmann *et al.* ([@ddw151-B26]) reported that knockdown of at least six genes in the Chr19p13.11 locus in Hela-Kyoto cells impacted DiI-LDL uptake, intracellular cholesterol levels or both. rs10401969 is located within an intron of SURP and G patch domain containing 1 (*SUGP1*), previously known as splicing factor 4 (*SF4*). Because splicing is a mechanism that regulates cholesterol homeostasis ([@ddw151-B27]) and genetic variants associated with variation in plasma LDLC levels can influence splicing of the key cholesterol metabolism genes 3-hydroxy-3-methylglutaryl-CoA reductase (*HMGCR*) and low-density lipoprotein receptor (*LDLR*) ([@ddw151-B28],[@ddw151-B29]), we sought to investigate whether genetic variation within a splicing factor itself ([@ddw151-B30]) can affect cellular cholesterol homeostasis. Thus, here we investigate whether SUGP1 may contribute to the relationship between rs10401969 and plasma lipids through the regulation of alternative splicing.

Results
=======

SUGP1 impacts cholesterol metabolism *in vitro*
-----------------------------------------------

To determine whether SUGP1 impacts cellular cholesterol metabolism, we transfected human hepatoma HepG2 and Huh7 cell lines with siRNAs targeting *SUGP1*, which reduced *SUGP1* transcript levels by 45--70% (*n* = 12) and protein levels by 72--91% (*n* = 2) ([Fig. 1](#ddw151-F1){ref-type="fig"}A and B). SUGP1 knockdown increased rates of DiI-LDL uptake 10--15% ([Fig. 1](#ddw151-F1){ref-type="fig"}C) and reduced APOB in the cell culture media ([Fig. 1](#ddw151-F1){ref-type="fig"}D), but did not alter APOE concentrations ([Supplementary Material, Fig. S1A](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). SUGP1 knockdown also reduced rates of cholesterol synthesis ([Fig. 1](#ddw151-F1){ref-type="fig"}E) and HMGCR enzyme activity ∼20% ([Fig. 1](#ddw151-F1){ref-type="fig"}F). Consistent with this observation, we also found that *SUGP1* transcript levels were positively correlated with variation in HMGCR enzyme activity in 118 human lymphoblastoid cell lines (*P* = 0.0215, *r*^2^= 0.04; [Fig. 1](#ddw151-F1){ref-type="fig"}G). To demonstrate the specificity of these effects, we performed a rescue experiment in which *SUGP1* was overexpressed in HepG2 cells after *SUGP1* knockdown ([Supplementary Material, Fig. S1B and S1C](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). As expected, *SUGP1* overexpression was able to reverse the effects of *SUGP1* knockdown on rates of DiI-LDL uptake ([Fig. 1](#ddw151-F1){ref-type="fig"}H) and APOB in the media ([Fig. 1](#ddw151-F1){ref-type="fig"}I). Similarly, *SUGP1* overexpression alone also reduced rates of DiI-LDL uptake ([Supplementary Material, Fig. S1D](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). In contrast, knockdown of *ATPase type 13A1* (*ATP13A1*) and *MAU2 sister chromatid cohesion factor* (*MAU2*), two additional genes within the Chr19p13.11 locus ([Supplementary Material, Fig. S1E](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)) whose expression levels are associated with rs10401969 ([@ddw151-B31]), did not produce consistent and statistically significant changes in measures of cellular cholesterol metabolism ([Supplementary Material, Fig. S1F and S1G](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). Figure 1.SUGP1 expression level impacts cellular cholesterol metabolism. HepG2 and Huh7 cells were reverse transfected with an NTC siRNA or Silence Select siRNAs against *SUGP1*, SUGP1-1 and SUGP1-2. After 48 hours, cells were collected, and various cellular phenotypes were measured. (**A**) *SUGP1* transcript levels were quantified by quantitative PCR (*n* = 6). (**B**) SUGP1 protein was detected by immunoblot and band density was quantified using Image J (*n* = 4), one representative blot shown. (**C)** DiI-LDL uptake was quantified by Fluorescence-activated cell sorting (*n* = 6). (**D**) APOB in the conditioned media was quantified by ELISA and normalized to total cellular protein quantified by a bicinchoninic acid assay (*n* = 9). (**E**) Rates of cholesterol biosynthesis were quantified using a radiolabeled precursor in Huh7 cells (*n* = 3), with values normalized to total cellular protein. (**F**) HMGCR activity in HepG2 cells was quantified by incubating lysed cells with 14C-HMG-CoA (precursor) to directly assess incorporation rates into 14C-mevalonate (product). Pmol of mevalonate formed was normalized to total protein (*n* = 6). (**G**) *SUGP1* transcript levels were quantified by expression array in 118 LCLs, normalized by array batch and corresponding covariates. HMGCR enzyme activity was measured in these same LCLs and tested for association with *SUGP1* transcript levels using linear regression in JMP 9.0. (**H** and **I**) HepG2 cells were reverse transfected with SUGP1-1 siRNA or NTC, and after 24 hours, cells were transfected with an SUGP1 overexpression construct (SUGP1-1 + O/E) or empty vector (SUGP1-1) and incubated for an additional 48 hours. LDL-uptake and APOB in the culture media were quantified (*n* = 6). All statistical analyses were performed in JMP 9.0. With the exception of I, ANOVA with post hoc two-tailed *t*-tests were used to identify differences between treatments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. All Ns reported are per cell type/per condition.

SUGP1 alters cholesterol metabolism *in vivo*
---------------------------------------------

To test the physiological relevance of SUGP1, we delivered murine *Sugp1* to the liver by hydrodynamic tail vein injection in CD-1 mice. After 7 days, hepatic overexpression of *Sugp1* was assessed. *Sugp1* transcript and protein levels were increased ([Fig. 2](#ddw151-F2){ref-type="fig"}A and B and [Supplementary Material, Fig. S2A](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). Fasting plasma lipids were measured and total cholesterol (TC), triglyceride and high-density lipoprotein (HDL) cholesterol were significantly increased, with a trend of elevated LDLC observed ([Fig. 2](#ddw151-F2){ref-type="fig"}C). Similar effects were also observed after 28 days of *Sugp1* overexpression ([Supplementary Material, Fig. S2B--S2D](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)), with greater hepatic *Sugp1* expression correlated with greater increases in TC (*P* = 0.01, *r*^2^= 0.53 and [Supplementary Material, Fig. S2E](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). In addition, we found elevated triglyceride secretion in the overexpressing animals after Polyoxamer 407 treatment ([Fig. 2](#ddw151-F2){ref-type="fig"}D**)**. Consistent with *in vitro* results, *Sugp1* overexpression resulted in greater hepatic Hmgcr enzyme activity ([Fig. 2](#ddw151-F2){ref-type="fig"}E), whereas we observed no change in hepatic *Hmgcr* transcript levels ([Supplementary Material, Fig. S2F](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). Figure 2.Hepatic Supg1 overexpression increases plasma cholesterol in mice. An Sugp1 overexpression (O/E) vector or an empty vector control was injected into the tail veins of CD-1 male mice (*n* = 4 or 5/condition). (**A**) *Sugp1* mRNA was quantified by quantitative PCR (qPCR) 7 days post injection. (**B**) SUGP1 protein levels in mouse livers were determined by western blot and normalized against glyceraldehyde-3-phosphate dehydrogenase as a loading control. (**C**) Plasma lipids were quantified by colorimetric assay, adjusted for percent change in body weight over time, and unpaired two-tailed *t*-tests were used to identify statistically significant differences between the residuals. (**D**) Plasma triglycerides were quantified by colorimetric assay before and 3 hours after injection with Polyoxamer 407. (**E**) Hepatic Hmgcr enzyme activity was quantified as described in Figure 1. (**F**) Hepatic *Hmgcr* splice variants were quantified by qPCR. Unpaired two-tailed *t*-tests were used to identify statistically significant differences \**P* \< 0.05, \*\**P* \< 0.01.

SUGP1 knockdown increases expression of alternatively spliced HMGCR transcripts
-------------------------------------------------------------------------------

Given the effects of SUGP1 knockdown on LDL uptake and HMGCR enzyme activity, and its putative role as a splicing factor, we postulated that SUGP1 might directly affect *LDLR* or *HMGCR* transcript structure. Because alternative splicing of *LDLR* is extensive and highly varied, we tested the four major *LDLR* splice variants, specifically, those lacking exons 3, 4, 12 or 14 ([@ddw151-B28]). SUGP1 knockdown did not produce consistent changes in expression levels of any of these *LDLR* transcripts *in vitro* ([Supplementary Material, Fig. S3A](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)).

To assess effects of SUGP1 on *HMGCR* structure, we first identified *HMGCR* splice variants expressed in primary liver tissue derived from human donors (*n* = 3), human hepatoma cell lines (HepG2, Hep3B and Huh7) and lymphoblastoid cell lines (LCLs) (*n* = 8) by RNAseq. In addition to the known *HMGCR* splice variants, which lack exon 13, *HMGCR13*(−), or exon 18, *HMGCR18*(−), we also detected transcripts with shortened versions of exons 11 (ex11b) and 18 (ex18b). Ex11b is missing 93 bp at its 5′ end, whereas ex18b is missing 45 bp at its 3′ end ([Fig. 3](#ddw151-F3){ref-type="fig"}A--C). Although *HMGCR11b* and *HMGCR18b* have a similar level of abundance, RT-PCR with primers specific for ex11b to ex18b failed to amplify a product ([Supplementary Material, Fig. S3B](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)), suggesting that these two splice events do not occur on the same transcript. SUPG1 knockdown resulted in statistically significant increases (14--49%) in *HMGCR11b, HMGCR18b* and *HMGCR18*(−) in human hepatoma cell lines transfected with *SUGP1* siRNAs ([Fig. 3](#ddw151-F3){ref-type="fig"}D). In contrast, there were no consistent changes in *HMGCR13*(−), the most abundant *HMGCR* splice variant, and a trend of increased *HMGCR13*(*+*). We found detectable expression levels of these splice variants in the mouse, and consistent with these effects, increased *Hmgcr* alternative splicing was observed after *Sugp1* overexpression *in vivo* ([Fig. 2](#ddw151-F2){ref-type="fig"}F). Figure 3.*SUGP1* knockdown increases expression levels of the known and novel *HMGCR* splice variants**.** Size selected polyA-purified RNA-seq libraries were prepared from human hepatoma cell lines (HepG2, Hep3B and Huh7), primary human liver tissue (*n* = 3 donors), and lymphoblastoid cell lines (*n* = 8 African American donors), and sequenced using paired-end sequencing. Sequences were aligned to the genome and the known transcriptome using TopHat, and instances of alternative splicing were identified at *HMGCR* exons 11, 13 and 18. Neither the *HMGCR11b* nor the *HMGCR18b* splice variant has been previously identified. Exon 11b is missing 93 bp at the 5′ end of exon 11, and exon 18b is missing 45 bp at the 3′ end of exon 18. (**A**) Diagram of canonical versus alternatively spliced junctions. Canonical splice junctions are shown in blue, and alternatively spliced junctions in green. Exons affected by alternative splicing are in red. Sequence alignment of junction spanning reads identifying *HMGCR11b* (**B**) and *HMGCR18b* (**C**). The reference sequence (blue) is shown at the bottom in bolded blue text. The canonical exon sequences are shown in black, and the novel exon 11b and 18b are in green. Due to space constraints, 40 bp of skipped sequence was omitted from the reference sequence for exon 11. (**D**) HMGCR splice variants quantified by real-time qPCR (*n* = 12) after 48 hours of SUGP1 knockdown by siRNA (SUGP1-1, SUGP1-2 or NTC control) in HepG2 and Huh7. Data are shown as relative fold change compared to NTC control. Student's *t*-test comparing the effect of SUGP1 knock-down on *HMGCR* splice variants compared to *HMGCR13*(*+*). \**P* \< 0.05; \*\**P* \< 0.01.

To determine whether these novel *HMGCR* splice variants are subject to non-sense-mediated decay (NMD), we treated HepG2 cells with cycloheximide, an inhibitor of NMD, and quantified *HMGCR* splice variants over 3 hours. *HMGCR18*(−) levels dramatically increased, whereas *HMGCR11b* and *HMGCR18b* transcripts levels remained unchanged, indicating that *HMGCR18*(−) abundance is likely regulated by NMD ([Supplementary Material, Fig. S3C](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). These findings suggest that the reduction in HMGCR enzyme activity observed after SUGP1 knockdown may be attributed to greater expression levels of the novel *HMGCR* splice variants.

SUGP1 regulates HMGCR alternative splicing and transcript stability
-------------------------------------------------------------------

SUGP1 is predicted to function as a splicing factor ([@ddw151-B30]). However, to date, the function of SUGP1 has not yet been validated. To determine whether SUGP1 regulates *HMGCR* alternative splicing, HepG2 and Huh7 cell lines were transfected with a mini-gene containing the *HMGCR* genomic sequence from intron 17 to 19 (*mHMGCR17-19*) following *SUGP1* knockdown ([Fig. 4](#ddw151-F4){ref-type="fig"}A). *HMGCR* transcripts derived from the mini-gene were quantified by quantitative PCR. *SUGP1* knockdown increased the relative expression levels of the mini-gene-derived *HMGCR18b* and *HMGCR18*(−) transcripts, compared to *HMGCR18*(*+*) transcripts *in vitro* ([Fig. 4](#ddw151-F4){ref-type="fig"}B). Figure 4.*SUGP1* knockdown modulates *HMGCR* alternative splicing and transcript half-life. (**A**) Diagram of the mini-gene construct and quantitative PCR (qPCR) primers used to directly test SUGP1 effects on *HMGCR* exon 18 alternative splicing. Red arrows indicate different forward primers within the cDNA sequence used to assay for alternative splice variants. (**B**) Mini-gene-derived *HMGCR* transcript ratios show an increase in alternative splice variants upon *SUGP1* knockdown. HepG2 and Huh7 cells were first transfected with SUGP1-1, SUGP1-3 or NTC siRNAs. After 24 hours, cells were transfected with the *HMGCR* exon 18 containing mini-gene construct and incubated for an additional 24 hours. Mini-gene-derived *HMGCR* transcripts were quantified by qPCR (*n* = 6 per condition). (**C**) *SUGP1* knockdown decreases transcript half-life. HepG2 cells were transfected with SUGP1 or NTC siRNAs, and actinomycin D was added after 48 hours to halt cellular transcription. *HMGCR* transcript levels were quantified over 24 hours, and half-life calculated as previously described. Data are represented as mean ± SEM. (**D**) Relative changes in *HMGCR* transcript half-life in cells transfected with one of the two SUGP1 siRNAs compared to NTC. \**P* \< 0.05, \*\**P* \< 0.01 indicate effects of *SUGP1* knockdown decrease *HMGCR11b* and *HMGCR18b* transcript half-life compared to *HMGCR13*(*+*). \**P* \< 0.05; \*\**P* \< 0.01.

We previously reported that HNRNPA1, another RNA binding protein, increases the relative abundance of *HMGCR13*(−) transcript compared to *HMGCR13*(*+*) transcript by promoting alternative splicing as well as preferentially stabilizing the *HMGCR13*(−) transcript ([@ddw151-B32]). To test whether SUGP1 also impacts *HMGCR* transcript stability, we treated HepG2 and Huh7 cell lines with actinomycin D upon *SUGP1* knockdown and measured endogenous *HMGCR* transcripts. *SUGP1* knockdown dramatically reduced *HMGCR* transcript half-lives ([Fig. 4](#ddw151-F4){ref-type="fig"}C and [Supplementary Material, Fig. S4A](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)); however, this effect was less pronounced for *HMGCR11b* and *HMGCR18b* than for *HMGCR13*(*+*) or *HMGCR13*(−) in HepG2 cells ([Fig. 4](#ddw151-F4){ref-type="fig"}D). No decay of *HMGCR18*(−) was detected after actinomycin D treatment, and thus half-life was not determined ([Supplementary Material, Fig. S4B](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). These results suggest that despite the overall reduction in *HMGCR* transcript stability, the increase in the relative ratio of the *HMGCR11b* and *HMGCR18b* transcripts over the canonical *HMGCR13*(*+*) after SUGP1 knockdown is likely due to both promotion of *HMGCR* alternative splicing and smaller reductions in the stability of the alternatively spliced transcripts.

rs10401969 modulates SUGP1 alternative splicing and protein levels
------------------------------------------------------------------

rs10401969, despite being located in SUGP1 intron 8, has not been associated with *SUGP1* transcript levels in any publically available eQTL dataset, including liver ([@ddw151-B33]). Thus, we postulated that rs10401969 may influence *SUGP1* transcript structure. Using RT-PCR and Sanger sequencing of cDNA from human hepatoma RNA, we detected a novel *SUGP1* splice variant lacking exon 8, *SUGP1 exon 8*(−) ([Supplementary Material, Fig. S5A](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). The rs10401969 C allele was associated with 20% greater *SUGP1* exon 8 skipping in LCLs derived from participants of the Cholesterol and Pharmacogenetics (CAP) clinical trial ([Fig. 5](#ddw151-F5){ref-type="fig"}A), whereas no difference in overall *SUGP1* expression levels was detected*.* Similar trends were detected in human livers derived from the St. Jude's Liver Repository ([Supplementary Material, Fig. S5B](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). Importantly, exon 8 skipping disrupts the open reading frame, introducing a stop codon after 27 base pairs, which we confirmed triggers non-sense-mediated decay because *SUGP1 exon 8*(--) levels increase in cycloheximide-treated HepG2 cells ([Fig. 5](#ddw151-F5){ref-type="fig"}B). In addition, we found that the rs10401969 C allele carriers also had reduced levels of SUGP1 protein compared to TT homozygotes (*P* = 0.01, *n* = 60, [Fig. 5](#ddw151-F5){ref-type="fig"}C and [Supplementary Material, Fig. S5C](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). However, there was no evidence that reduced SUGP1 protein in C allele carriers was due to greater protein decay rates ([Supplementary Material, Fig. S5D and S5E](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). Figure 5.rs10401969 regulates *SUGP1 exon 8* skipping by modulating HNRNPA1 binding. (**A**) The rs10401969 C allele modulates increases in SUGP1 exon 8 skipping compared to the reference allele by ∼20%. *SUGP1* transcript levels were quantified by qPCR in LCLs genotyped for rs10401969 (CT *n* = 18; TT *n* = 30). Total *SUGP1* was quantified by qPCR assays for exon 7--9 (Ex7-9) and exon 7--8 (Ex7-8) junctions. The relative ratio of Ex7-9 and Ex7-8 is shown. (**B**) To measure non-sense-medicated mRNA decay, HepG2 cells were treated with cycloheximide (1 μg/ml), and *SUGP1 8*(−) and *8*(+) transcripts were quantified over 24 hours by qPCR. \**P* \< 0.05, two-tailed paired *t*-test, *n* = 3. (**C**) SUGP1 protein levels from CAP LCLs genotyped for the rs10401696 SNP (CT *n* = 28, TT *n* = 32) were measured by western blot. Band densities were calculated by Image J and normalized to a β-actin protein levels. (**D**) Scheme of the *SUGP1* mini-gene (*mSUGP1*) construct containing the genomic fragment of *SUGP1* introns 7--8 with the rs10401969 minor allele (C) introduced through site directed mutagenesis. (**E**) HepG2 and Huh7 (*n* = 3) cell lines were transfected with either the rs10401969 'T' or 'C' allele *mSUGP1* construct and mini-gene-derived transcripts quantified by qPCR after 48 hours. Values shown are the relative ratios of *mSUGP1 exon 8*(−) to *mSUGP1 exon 8*(+) transcripts are shown. (**F**) RNA gel shift assay was performed in triplicate with rs10401969 3' biotin-labeled RNA oligos and either His-tagged HNRNPA1 or SRSF1 proteins. The upper panel shows 30-minute exposure image of a representative gel while the lower panel is a 2-minute exposure of the same gel.

GWAS-identified SNPs are often assumed to be in LD with functionally relevant SNPs and not the causal variant themselves. Although rs10401969 is 80 base pairs downstream from the exon 8 splice donor, there are no other SNPs in high LD (*r*^2^\> 0.9) with rs10401969 that are predicted to modulate exon 8 skipping. We tested whether rs10401969 directly alters exon 8 alternative splicing using an *SUGP1* mini-gene (*mSUGP1*) construct ([Fig. 5](#ddw151-F5){ref-type="fig"}D). Transcripts derived from the mini-gene with the rs10401969 C allele had a higher frequency of exon 8 skipping than those expressed from the T allele ([Fig. 5](#ddw151-F5){ref-type="fig"}E), consistent with our observations in the CAP LCLs. Using Human Splicing Finder ([@ddw151-B34]), we noted that rs10401969 lies immediately adjacent to a predicted binding site for HNRNPA1, a splicing factor that we have previously implicated in cholesterol metabolism ([@ddw151-B32]). Using an RNA electrophoretic mobility shift assay with probes containing *SUGP1* intron 8 with either the rs10401969 C or T allele, we found that the C allele had 27% stronger binding affinity to HNRNPA1 protein compared to the T allele as indicated by reduced intensity of the free probe ([Fig. 5](#ddw151-F5){ref-type="fig"}F and [Supplementary Material, Fig. S5F and S5G](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)). As a control, we also performed RNA electrophoretic mobility gel shift assay (RNA EMSA) with serine/arginine-rich splicing factor 1 (SRSF1), a splicing factor whose binding to *SUGP1* is not predicted to be disrupted by rs10401969; and as expected, observed no differences in SRSF1 binding between alleles ([Fig. 5](#ddw151-F5){ref-type="fig"}F and [Supplementary Material, Fig. S5G](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)).

Inter-individual variation in SUGP1 transcript levels is correlated with variation in HMGCR alternative splicing in an rs10401969 allele-dependent fashion
----------------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether endogenous variation in *SUGP1* expression was associated with variation in *HMGCR* alternative splicing, we quantified *SUGP1* and *HMGCR* splice variants in 57 LCLs. We found evidence of a positive correlation between *SUGP1* transcript levels with variation in *HMGCR11b/Total HMGCR* (*P* = 0.0045, *r*^2^= 0.14) and *HMGCR18b/Total HMGCR* ratios (*P* = 0.0018, *r*^2^= 0.16), whereas there was no association with either *HMGCR13*(−)*/Total HMGCR* or *HMGCR18*(−)*/Total HMGCR* ratios. Interestingly, we found that this relationship was modified by rs10401969. As shown in [Figure 6](#ddw151-F6){ref-type="fig"}, correlations between *SUGP1* and *HMGCR11b/Total* (*P* = 6.3e ^−^ ^5^, *r*^2^= 0.51) or *HMGCR18b/Total* (*P* = 0.0002, *r*^2^= 0.46) were observed in rs10401969 minor allele carriers only (*n* = 25), with statistically significant interaction terms. Figure 6.*SUGP1* and *HMGCR* alternative splicing are correlated in an rs10401969-dependent manner. *SUGP1* and *HMGCR* transcripts, *H11b, H18b, H18*(*+*)*, H13*(−) and total *HMGCR*, were quantified in LCLs by quantitative PCR, and linear regression was used to identify the relationship between quantile normalized *SUGP1* transcript levels and *HMGCR* alternative splicing. All statistical analyses were performed in JMP 9.0 using a general linear model.

Discussion
==========

Here, we sought to determine whether *SUGP1* contributes to the relationship between rs10401969 and plasma lipids through regulation of alternative splicing. Through cellular and animal studies, we found that SUGP1 is a novel regulator of cholesterol metabolism that post-transcriptionally modifies *HMGCR*, impacting cholesterol synthesis. In addition, we show that rs10401969 is a functional variant, regulating *SUGP1* alternative splicing. Together, these results implicate SUGP1 as a contributor to inter-individual variation in plasma cholesterol.

SUGP1 was first identified as a putative splicing factor based on domain composition analysis ([@ddw151-B30]). The SUGP1 protein is predicted to contain two SURP motifs, domains of alternative splicing regulators thought to be involved in RNA binding ([@ddw151-B35]), as well as a G-patch domain, a region of six highly conserved glycine residues commonly found in eukaryotic RNA-processing proteins ([@ddw151-B36]). Although SUGP1 has been shown to co-purify with components of the spliceosome in multiple studies ([@ddw151-B37]), prior to this report, no functional studies of SUGP1 have been published. Here, we confirm that manipulation of SUGP1 does lead to changes in the structure and stability of some transcripts, consistent with its annotation as an RNA regulatory protein.

Importantly, we found that one of SUGP1's targets is *HMGCR*, a key cholesterol regulatory gene. SUGP1 knockdown increased expression levels of several alternatively spliced *HMGCR* transcripts, *HMGCR11b, HMGCR18b* and *HMGCR18*(−) by both promoting exon skipping and reducing transcript stability in a splice variant-dependent fashion*.* Although the open reading frame is retained in these splice variants, they omit a portion of the catalytic domain, and if translated we predict these variants to encode HMGCR isoforms with reduced or abolished enzyme activity. We found that *in vitro* SUGP1 knockdown reduced HMGCR enzyme activity, rate of cholesterol synthesis, and APOB in the culture media, as well as increased LDL uptake. Consistent with these effects, we observed elevated plasma cholesterol and hepatic *Hmgcr* expression, which could be attributed to the increased hepatic triglyceride secretion, elevated Hmgcr enzyme activity and reduced expression of *Hmgcr* splice variants after Sugp1 overexpression *in vivo.* Together, these data strongly support the likelihood that *SUGP1* is a novel cholesterol regulatory gene.

We also demonstrate that rs10401969, a GWAS identified SNP associated with plasma lipids, CAD and hepatic steatosis ([@ddw151-B4],[@ddw151-B22],[@ddw151-B23],[@ddw151-B40],[@ddw151-B41]), regulates *SUGP1* alternative splicing. Located 80 bp upstream of the exon 8 splice donor, we found that the rs10401969 C allele promotes binding of HNRNPA1, a well known factor that stimulates alternative splicing, and induces skipping of *SUGP1* exon 8. Loss of exon 8 disrupts the open reading frame, stimulating non-sense-mediated decay of the alternatively spliced transcript. SUGP1 knockdown both increases *HMGCR* alternative splicing and reduces overall *HMGCR* transcript stability, consistent with our observation that the correlation between inter-individual variation in *SUGP1* expression quantified in the LCLs with variation in *HMGCR* alternative splicing differs by rs10401969 genotype. Together, these observations support the likelihood that rs10401969 itself is a functional variant that affects SUGP1 regulation of *HMGCR*. Because HMGCR encodes the rate-limiting step of the cholesterol biosynthesis pathway, knockdown also reduced cholesterol synthesis *in vitro*, whereas overexpression increased plasma cholesterol *in vivo*. These relationships are consistent with many GWAS studies showing an association between the rs10401969 C allele and reduced plasma cholesterol ([Supplementary Material, Fig. S6](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1)).

These results suggest that SUGP1-induced changes in cholesterol metabolism are mediated by the regulation of *HMGCR*; however, RNA-binding proteins are not usually specific for a single target gene. For example, although it is tempting to conclude that the reduced cholesterol synthesis stimulates LDL uptake by promoting SREBF2 activation, there is no evidence to suggest that these are cause and effect. We failed to observe increased expression levels of SREBF2 target genes including *MVK, LDLR* and *PCSK9* (data not shown) after SUGP1 knockdown *in vitro*, indicating a lack of SREBF2 activation. Although greater hepatic *Hmgcr* transcript levels (another SREBF2 target gene) were detected after Sugp1 overexpression *in vivo*, this up-regulation could be attributed to direct effects of Sugp1 on *Hmgcr* transcript stability. Further study is required to determine whether SUGP1 targets other key cholesterol regulators beyond *HMGCR* and contributes to the overall cholesterol phenotype observed.

As previously described, rs10401969 is in a large LD block containing many genetic variants in individuals of European ancestry, and one or more of these variants could have a functional impact. Additional fine mapping and conditional association analyses in ethnic populations with smaller haplotypic blocks in this region could help reveal the number of functional variants that contribute to the genetic association signals in individuals of European ancestry. In particular, rs10401969 is in strong LD with a functional variant in *TM6SF2*, p.Glu167Lys*.* A trio of recent studies utilizing human genetics and functional studies in cellular and animal models all implicate *TM6SF2* as a causative functional gene within the Chr19.13p11 locus. Using an AAV model, Holzmen *et al.*(2014) found that overexpression of human *TM6SF2* in C57BL/6J mice increased plasma TC, LDLC and triglycerides and reduced HDL cholesterol after 5 days. Consistent with these findings, Kozlitina *et al.*([@ddw151-B23]) reported that *Tm6sf2* knockdown reduced plasma cholesterol and triglycerides after 8 weeks, and the effect was attributed to a defect in VLDL secretion. *TM6SF2* knockdown was also shown to reduce secretion of triglyceride rich lipoproteins ([@ddw151-B24]), whereas TM6SF2 overexpression was reported to increase cholesterol synthesis ([@ddw151-B42]) in human hepatoma cell lines. Notably, these studies suggest that *TM6SF2* is the only causative gene within the locus. Conditional analyses found that the *TM6SF2* p.Glu167Lys variant remained significantly associated with plasma LDLC and triglycerides when controlled for other SNPs within the locus, whereas the signal of these other SNPs (including rs10401969) was abolished after controlling for the *TM6SF2* variant ([@ddw151-B22],[@ddw151-B23]). In addition, using a panel of \>200 human livers, variation in the expression of *TM6SF2*, but not any of the other 18 genes tested within the locus, was correlated with both rs10401969 genotype and variation in hepatic triglyceride content ([@ddw151-B24]).

Given these findings, it is challenging to interpret our results and the relevance of SUGP1 and rs10401969. Because the function of TM6SF2 has not been fully established, it is possible that the effect of TM6SF2 on lipid metabolism may be mediated (at least in part) by SUGP1 or vice versa. However, in preliminary studies, we have failed to identify any direct effect of *TM6SF2* knockdown on *SUGP1* expression or vice versa (data not shown). In addition, LCLs do not express *TM6SF2*. Thus, the relationships we observed between *SUGP1* and HMGCR enzyme activity and alternative splicing using these cells cannot be attributed to a potential effect of either the *TM6SF2* SNP or gene. In addition, although our results do not dispute the importance of the *TM6SF2* gene or variant as a causative gene within the 19p13.11 locus, the consistency in our findings across cellular, animal and genetic analyses supports the conclusion that *SUGP1* is a novel cholesterol regulator. Finally, although the conditional genetic analyses suggest that the effect of rs10401969 alone is not sufficient to impact plasma lipids *in vivo*, they do not discount the possibility that rs10401969 may act in an additive or synergistic manner with the *TM6SF2* SNP, especially given the high LD of the two SNPs. The minor allele of each SNP reduces SUGP1 or TM6SF2 protein levels, and these two proteins have concordant effects on plasma cholesterol as overexpression of each gene alone increases plasma cholesterol. Thus, the relationships observed between genetic variation within this locus and plasma cholesterol may be due to the combined effect of *SUGP1* and *TM6SF2*.

In summary, our results have shown SUGP1 to be a multi-functional RNA regulatory protein that modulates expression levels of several *HMGCR* splice variants, altering HMGCR enzyme activity and impacting both cellular and *in vivo* cholesterol metabolism. Furthermore, the finding that rs10401969, a GWAS-identified SNP associated with plasma LDLC and CAD, regulates *SUGP1* implicates SUGP1 as a potential contributor to this genetic association. Overall, the present results reinforce the role of genetic regulation of transcript structure in pathways affecting cholesterol metabolism and cardiovascular disease risk.

Materials and Methods
=====================

Cell culture
------------

HepG2, Hep3B and Huh7 cells were obtained from the American Type Culture Collection and grown under standard culture conditions. LDL was isolated as previously described ([@ddw151-B43]). Cells were exposed in replicate to conditions of sterol depletion (10% lipoprotein deficient serum and 2 µ[m]{.smallcaps} activated simvastatin), and after 24 hours, 50 µg/ml LDLC was added for an additional 24 hours. Immortalized LCLs (*n* = 54) were derived from donors of the CAP clinical trial and grown as previously described ([@ddw151-B44]).

siRNA transfections and cellular measurements
---------------------------------------------

*SUGP1, ATP13A1* and *MAU2* knockdown were achieved using the Ambion Silence Select siRNAs (SUGP1-1: s33721, SUGP1-3: s33722, ATP13A1: s32750, MAU2: s225955) or non-targeting control (NTC: AM4611) according to the manufacturer's protocol. Forty-eight hours after knockdown, RNA was isolated. cDNA was synthesized and transcripts were quantified by quantitative PCR with assays shown in [Supplementary Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1). Values were normalized to *CLPTM* as described ([@ddw151-B44]). For rescue experiments, cells were transfected in replicate with SUGP1-1 siRNA or NTC as described above. Forty-eight hours post transfection, cells SUGP1-1 siRNA treated cells were transfected with either the SUGP1 overexpression plasmid (pCMV-SUGP1) or an empty vector control (pCMV) and incubated for an additional 48 hours. APOB and APOE were quantified in triplicate by sandwich-style ELISA in culture media. HMGCR enzyme activity and DiI-LDL uptake were quantified as previously described ([@ddw151-B44],[@ddw151-B45]). Cholesterol synthesis was measured by the conversion of \[1-^13^C\] sodium acetate to ^13^C-labeled cholesterol as described ([@ddw151-B46]). Analysis of variance with post hoc two-tailed paired *t*-tests were used to determine statistically significant differences between treatments.

*In vivo* study
---------------

An *Sugp1* overexpression construct was created by subcloning the murine *Sugp1* gene (purchased from Origene) into the pLIVE-MCS vector (Mirus Bio). *Sugp1*-pLIVE was injected (25 μg) into the tail vein of 6-week-old CD-1 male mice (*n* = 10; Charles River Laboratories) using the TransIT-EE hydrodynamic gene delivery system (Mirus Bio), as previously described ([@ddw151-B47]). In a second set of CD-1 male mice (*n* = 10), the empty vector was injected to serve as the negative control. Five mice for each construct were euthanized at 7 and 28 days after injection by cardiac puncture. Animal studies were approved by the Children's Hospital Oakland Research Institute Animal Care and Use Committee and conform to all regulatory standards. Whole blood, liver and plasma were collected. Plasma cholesterol was quantified using a LIASYS 330 chemistry analyzer (AMS Diagnostics). Hepatic gene expression levels were quantified as described above, with values normalized to the geomean of *Clptm1* and *Rplp0*. All RNAs were DNaseI treated during isolation. Hepatic Sugp1 protein levels were quantified by Western blot analysis.

RNA electrophoretic mobility gel shift assay (RNA EMSA)
-------------------------------------------------------

3′ end-biotinylated RNA oligonucleotides were synthesized from Sigma-Aldrich. Purified His-tagged human recombinant HNRNPA1 and SRSF1 proteins were purchased from Prospec and ProteinOne. RNA gel shift assay was performed using LightShift Chemiluminescent RNA EMSA kit (Thermo Scientific). RNA oligos with either the SUGP1 rs10401969 'T' or 'C' allele were incubated for 30 minutes in the presence or in the absence of either His-HNRNPA1 or His-SRSF1 protein in 1x binding buffer, 5% glycerol, 2 µg tRNA, and 6.25 n[m]{.smallcaps} biotin-labeled RNA oligos. 5x loading dye was added to each reaction, loaded onto a 4--20% Novex® TBE Gels (Life Technologies), and run at 100 V for 2 hours in 0.5x Novex® TBE Running Buffer (Invitrogen) at 4 °C. The RNA--protein complexes were transferred from the gel to a nylon membrane (Thermo Scientific) at 35V for 40 minutes in a 4 °C cold room, and crosslinked using the Stratalinker UV crosslinker (Stratagene). Biotin-labeled RNA oligos were detected by the Chemiluminescent Nucleic Acid detection Module (Thermo Scientific), and quantified using the GelQuant.NET software.

SUGP1 and HMGCR mini-gene construct
-----------------------------------

To create the *SUGP1* and *HMGCR* mini-genes, *SUGP1* introns 7--8 and *HMGCR* introns 16--19 were cloned into pDEST exon-trap vector provided by Dr. Stephan Stamm. The plasmids were DNA sequence verified. The *SUGP1* mini-gene was co-transfected into HepG2 and Huh7 cells with the HNRNPA1 overexpression plasmid. The *HMGCR* mini-gene was co-transfected one of the two *SUGP1* targeting siRNA or NTC.

Identification of novel HMGCR splice variants
---------------------------------------------

Whole transcriptome sequencing (RNA-seq) was performed on LCLs from eight African American individuals (seven female and one male) as previously described ([@ddw151-B48]). Libraries were sequenced on an Illumina GAII machine and aligned to hg19 using TopHat v1.2.0 and Bowtie v0.12.7 ([@ddw151-B49],[@ddw151-B50]). Splice junctions detected by TopHat were compared to Ensembl v61 annotations to identify potentially novel junctions in *HMGCR*. From this analysis, two novel splice variants were identified with truncated versions of exons 11 and 18 using both direct evidence of junction spanning reads, and indirect evidence based the distance of paired end reads. Novel junctions were validated using RT-PCR with Sanger sequencing. The effect of SUGP1 on the stability of these *HMGCR* transcripts was assessed in HepG2 and Huh7 cells incubated with actinomycin D, with transcript half-life calculated as previously described ([@ddw151-B48]).

Supplementary Material
======================

[Supplementary Material](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw151/-/DC1) is available at *HMG* online.
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